Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7692712 | 1.00 | ALDH1A1 (0.33) | ALDH1A1LMNAALOX15BLMPMP22 | |
| SCHEMBL30073113 | 0.89 | TSHR (0.35) | ALDH1A1MAPTKMT2A | |
| SCHEMBL29278313 | 0.89 | TSHR (0.35) | ALDH1A1MAPTKMT2A | |
| SCHEMBL17094648 | 0.84 | F2 (0.30) | — | |
| SCHEMBL1698329 | 0.75 | — | — | |
| SCHEMBL1160500 | 0.75 | — | — | |
| SCHEMBL31519368 | 0.73 | — | — | |
| SCHEMBL20641576 | 0.71 | LMNA (0.35) | ALDH1A1LMNAALOX15BLMPMP22 | |
| SCHEMBL30073299 | 0.71 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL1671160 | 0.71 | ALDH1A1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024012568-A1 | A KEY INTERMEDIATE FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND PREPARATION METHOD THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-18 | — | — | WO | claimed |
| WO-2024012568-A1 | A KEY INTERMEDIATE FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND PREPARATION METHOD THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-18 | — | — | WO | disclosed |
| US-8124780-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| CN-101160306-B | Benzimidazole compounds | EISAI R&D MAN CO LTD | 2011-11-02 | — | — | CN | disclosed |
| EP-1870409-B1 | BENZIMIDAZOLE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2010-05-12 | — | — | EP | disclosed |
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | MIYAZAWA SHUHEI | 2009-08-13 | — | — | US | disclosed |
| US-7425634-B2 | Benzimidazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| CN-101160306-A | Benzimidazole compounds | EISAI R&D MAN CO LTD (JP) | 2008-04-09 | — | — | CN | disclosed |
| EP-1870409-A1 | BENZIMIDAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070015782-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-18 | — | — | US | disclosed |
| US-20070010542-A1 | Benzimidazole compound | EISAI CO., LTD. | 2007-01-11 | — | — | US | disclosed |
| EP-1354878-B1 | Tetrahydroquinoline derivatives having selective activity for retinoid x receptors | ALLERGAN INC (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1354878-A2 | Tetrahydroquinoline derivatives having selective activity for retinoid x receptors | Allergan, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| EP-1117648-B1 | TETRAHYDROQUINOLINE DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS | ALLERGAN INC (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2001070662-A2 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN , INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1117628-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan Sales, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-1117648-A1 | TETRAHYDROQUINOLINE DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS | Allergan Sales, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020397-A1 | TETRAHYDROQUINOLINE DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| WO-2000020370-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| US-6048873-A | SKIN DISORDERS | ALLERGAN SALES, INC. (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010542-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | ALDH1A1 1028/4885LMNA 3526/4885ALOX15 232/4885 |
| US-20090203911-A1 | BENZIMIDAZOLE COMPOUND | HRH2, HRH4, HRH1 | ALDH1A1 1053/4885LMNA 3603/4885ALOX15 358/4885 |
| US-20070015782-A1 | Benzimidazole compound | HRH2, GIPR, HRH4 | ALDH1A1 1028/4885LMNA 3526/4885ALOX15 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.